Science Corporation’s brain tech is worth $3.5 billion after new funding

Startups & Funding

Science raises $400 million as PRIMA advances toward the US

Science’s $400 million Series D values the start-up at $3.5 billion, advances PRIMA toward US use, and funds early planning for a cultured-neuron and silicon brain interface.

By
Tom Whitfield
Filed
Channel
Startups & Funding
Read
4 min read

Tom Whitfield

Science Corporation said in a company blog post that it raised a $400 million Series D. A person familiar with the deal told TechCrunch that the round valued the brain-technology start-up at $3.5 billion.

The company identified Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech as investors. The announcement disclosed no revenue, shipments, unit pricing or manufacturing capacity for PRIMA or the planned brain interface. The $3.5 billion number therefore represents an investor valuation, not a reported measure of commercial scale.

The financing covers two distinct development paths rather than a single finished platform. Science already offers a vision-restoration device in Europe while designing human trials for a more experimental system that connects cultured neurons with silicon.

Who founded Science and what does its background explain?\n

Max Hodak founded Science in 2021 after serving as Neuralink’s president. Hodak had talked his way into a graduate neuroscience laboratory as a college student and has pursued biotechnology ever since. He co-founded Science to leverage new technologies to understand and interact with the brain.

His background connects the company’s semiconductor ambitions with its medical focus. Science seeks to translate brain research into implantable or wearable technology rather than remain a laboratory program. Hodak’s neuroscience and biotechnology experience supplies the foundation for that approach.

What can PRIMA do today?

Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device has approval in Europe and is available in Germany. For a brain-technology company, PRIMA provides the clearest evidence of present-day product execution.

PRIMA’s commercial status should not be confused with the broader program. European approval and German availability establish current regulatory and market access in those places, but they do not establish US approval or wide distribution. The source identifies no pricing, reimbursement, shipment or manufacturing-volume figures for the device.

At TechCrunch Disrupt, Hodak announced that PRIMA is now being trialled in patients with Stargardt’s disease, another blindness-causing condition. The study extends the device’s clinical development beyond its initial macular-degeneration use, but trial participation does not equal regulatory approval or commercial availability.

PRIMA therefore stands as Science’s current product and early commercial foothold, while its expansion into additional conditions remains investigational.

What must happen before PRIMA can enter the US market?\n

Science aims to bring PRIMA to the United States through the FDA’s Humanitarian Device Exemption. The company describes that route as a way to use experimental medical technology for rare conditions. This creates a distinct pathway for a device that already has European approval but still lacks US authorization.

Science says it has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough for the company to seek approval to use PRIMA on people in the United States. Accepting that rationale allows Science to pursue an HDE request; it does not mean the FDA has approved PRIMA for US use.

The Stargardt trial does not change that regulatory position because the source states no FDA authorization for US use in that condition. The announced study and the HDE process therefore remain separate workstreams, with the latter framed around advanced macular degeneration in both eyes. The device’s broader disease reach cannot be inferred from either European approval or the start of another trial.

US commercialization consequently depends on FDA action and disease-specific access, not on Europe’s approval alone.

How far is the brain interface from human use?

Science’s founding purpose reaches beyond vision restoration. The company wants to connect directly with the human brain through a bio-hybrid sensor that combines cultured neurons with silicon. PRIMA uses a chip for a defined eye condition, while the sensor seeks a broader interface with neural tissue.

Science is currently designing its initial human trials with Yale neurosurgery professor Murat Günel. Günel told TechCrunch that the sensor could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses. The proposal remains prospective, with no trial start date, participant count, efficacy result or regulatory filing disclosed.

That leaves the sensor on a research path rather than a commercial path. PRIMA offers an approved device, an existing European market presence and a stated US regulatory strategy. The neuron-silicon system offers a longer-horizon clinical program, and its proposed neurological applications remain hypotheses until human testing produces evidence.

With the $400 million round completed, two proof points now matter: an FDA decision on US use of PRIMA and the start of initial human trials for the neuron-silicon sensor. Competitive credibility will hinge on those steps because the announcement disclosed no shipment, pricing or manufacturing-capacity figures for either program.

Source: techcrunch.com

Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Staff writer covering companies, deals and strategy in Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.

1,026 articles

Related articles

« Previous articleNext article »